SARS-Cov-2 infection in cancer patients, susceptibility, outcome and careArticle Published on 2022-11-012022-11-15 Journal: The American journal of the medical sciences [Category] COVID19(2023년), SARS, 진단, [키워드] anti-cancer treatment antibody benefit Cancer Cancer patients cancers Care coronavirus COVID-19 COVID-19 pandemic doses Factor generate healthy hematologic impacted implication increased risk individuals Infection knowledge observation outcome Pandemics Patient patients Perception problem response to vaccination risk SARS-CoV-2 SARS-COV-2 infection shown susceptibility Vaccines. virus [DOI] 10.1016/j.amjms.2022.05.017 PMC 바로가기
Observational Study of Receptor Binding Domain Spike Antibody Responses to 3 SARS-CoV-2 Vaccinations in Noninfected Subjects: Parallel Neutralizing Antibody and Cardiac Troponin I and T ObservationsArticle Published on 2022-10-292022-11-15 Journal: The journal of applied laboratory medicine [Category] COVID19(2023년), SARS, 진단, [키워드] antibody Biotechnology blood specimen cardiac cardiac troponin change collected Concentration concentrations Decline dose doses Effectiveness ET Healthcare increase janssen kinetic Moderna myocardial injury Neutralizing observation Pfizer platform point-of-care postvaccination Protein Pylon 3D RBD Receptor binding domain response SARS-CoV-2 seronegative specimens spike subject subjects troponin vaccination Vaccinations Vaccine were measured [DOI] 10.1093/jalm/jfac053 PMC 바로가기
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 VaccineArticle Published on 2022-10-252022-11-15 Journal: ACS Nano [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, [키워드] ACM acute respiratory syndrome adverse effect airway antibodies antibody antigen presenting cells artificial Beta Beta spike C57BL/6 cell membrane clinical symptom clinical trial component conditions coronavirus coronavirus disease COVID-19 CpG cross-neutralizing current delivery of cargo dendritic cells dose doses evaluate evaluated Formulation generate Generation Good hamster hamsters immune responses immunization immunogenic induce Infection initiated interval intranasal mice neutralize neutralizing antibody neutralizing responses New omicron Phase 1 polymersome Practice PROTECT reduction repeated Safety SARS-CoV-2 second serum IgG spike Spike protein Spike-based vaccine Support Toxicity upper respiratory tract Vaccine vaccine. variants viral clearance Viral load virus weight loss wild type [DOI] 10.1021/acsnano.2c06350 PMC 바로가기
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance – VISION Network, 10 States, December 2021-August 2022Article Published on 2022-10-212022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Against Analysis antibody antivirals B.1.1.529 benefit booster booster dose cause circulating Committee component conditions COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness eligible Hospitalization Hospitalized immunocompromising condition Mask moderate molecular test mRNA network nonpharmaceutical intervention offered omicron Person positive Practice predominant Prophylactic protection Protective receive recipient recommendation recommendations reduced Restricting SARS-CoV-2 therapy vaccination Vaccine variant virus [DOI] 10.15585/mmwr.mm7142a4 PMC 바로가기
SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipientsArticle Published on 2022-10-192022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] age anti-spike antibody antibodies Antibody titer booster conducted COVID-19 COVID-19 vaccine detectable dose doses fourth dose had more humoral immune response IQR kidney transplant recipients liver transplant no statistical difference Organ transplant participant patients proportion receiving recipient recipients regimen retrospective SARS-CoV-2 SARS-CoV-2 vaccine significantly higher solid-organ transplant Solid-organ transplantation SOT tested third dose vaccination. Vaccine vaccine doses vaccine injection [DOI] 10.1016/j.vaccine.2022.08.065 PMC 바로가기
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19Article Published on 2022-10-192022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% CI Administered administration Adverse affected analysed antiviral therapy Antiviral treatment ARMS baseline changed Combination combination therapy concentrations conducted coronavirus 2 COVID-19 COVID-19 pandemic Day Dose escalation doses double-blind double-blind trial drug level effective Efficacy evaluate the effect event Favipiravir healthy Interaction Lopinavir-ritonavir measure monotherapy Odds ratio Outpatient participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial placebos plasma primary analysis Primary outcome provided randomised recruited reduced respiratory SARS-CoV-2 SARS-CoV-2 viral load significant interaction significantly study population symptom onset the mean trajectory Treatment undetectable United Kingdom Viral load virus [DOI] 10.1371/journal.pmed.1004120 PMC 바로가기
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy AdultsArticle Published on 2022-10-182022-11-15 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CL acid administration adverse event affected agent Antiviral assessment AUC C max COVID-19 demonstrated dose doses drug-drug interaction Effect ensitrelvir first-in-human Food Intake geometric increase in Infection inhibitor Japanese mild in severity MOST novel oral dosing P450 participant Participants participants with SARS-CoV-2 pharmacokinetics phase 1 study Placebo plasma proportionality protease Protease inhibitor protease inhibitor. Randomized reduced resolved Safety SARS-CoV-2 selective single dose substrate T max Tolerability Treatment viral replication [DOI] 10.1128/aac.00632-22 PMC 바로가기
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infectionArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, [키워드] assays BNT162b2 BNT162b2 vaccine class correlated demonstrated develop dose doses epitope exhibited Frequency greater healthcare worker healthy IFN-γ IgG response IL-2 IL2 Immunity individual infected with SARS-CoV-2 Infection Interferon-gamma interleukin-2 magnitude Moderna mRNA-1273 vaccine mononuclear cell mRNA-1273 N and M nine participant Participants PCR testing peptide Peripheral blood Pfizer-BioNTech positive Post-infection Proteins proteome repeated responders response responses against robust S glycoprotein S1 and S2 S2 subunit SARS-CoV-2 SARS-COV-2 infection structural protein subunit subunits T cell response T-cell Response the SARS-CoV-2 uninfected vaccination vaccinee was determined were expressed with COVID-19 [DOI] 10.1371/journal.pone.0276241 PMC 바로가기
Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective studyArticle Published on 2022-10-132022-11-15 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome administration anti-RBD antibody BNT-162b2 ChAdOx1 vaccine coronavirus coronavirus disease COVID-19 diabetes disease dose doses Effect Efficacy first dose IgG Immunity vaccine Immunoglobulin Infection kidney kidney transplant liver liver transplant Liver transplant. Local no difference older patient Organ transplant Patient platform Primary outcome Prospective Study prospectively studied question recipient reduced resulting SARS-CoV-2 SARS-CoV-2 vaccination second dose secondary endpoint seroconversion rate shown side significantly solid organ transplant spread to systemic adverse event the RBD the spike protein the vaccine trials unresponsiveness vaccination Vaccine vaccine doses vaccine platform [DOI] 10.1186/s12879-022-07764-x PMC 바로가기
Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patientsArticle Published on 2022-10-062022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] ACE2 binding addition administration analysed anti-RBD B.1 binding BNT162b2 boost immunity cellular Control controls COVID-19 COVID-19 vaccination Decline declining Delta detectable dialysis dose doses group Haemodialysis Haemodialysis patient humoral humoral immune response Humoral immunity IgG IgG response immune immune evasion immune protection immunoassays Immunocompromised individual individuals information interferon γ knowledge longitudinal longitudinal response maintain mixed mRNA vaccination mRNA mRNA vaccination mRNA-1273 mucosal omicron Omicron variant of concern Patient patients Prevent protective immunity protective immunity. RBD reached regimen remained respond poorly restored SARS-CoV-2 vaccination SARS-CoV-2 variant second vaccination severe COVID-19 significantly increased spike subsequent Support T-cell Response tested the receptor-binding domain vaccination Vaccine variant variants of concern [DOI] 10.3389/fimmu.2022.1004045 PMC 바로가기